Regulaxis SAS France

Regulaxis SAS is a French biotech company created in 2013 to develop innovative therapies for human clinic based on new synthetic peptides regulating cell growth and differentiation.

Regulaxis is specialized in the regulation of cell proliferation and/or cell differentiation. The potential therapeutic applications covered by our patents are very broad, especially in the areas of joint/bone or nerve cell regeneration, but also in cancer and related metabolic diseases (diabetes, obesity …).
Our mission is to grant licenses of innovative molecules in a pharmaceutical company after completion of phase II clinical proof of concept.

Regulaxis is strategically focused only on high unmet medical needs but has elected as its first priority:
regeneration of articular cartilage using intra-articular injections of its lead candidate REG-O3.

Company Size (Fulltime employees)
Year of foundation
2013
Looking for
Please specify your partnering goal
Investor or licensee
Funding Status
1.1 mEUR (10 mRMB)
Now raising (In USD)
25 mUSD
Headquartner in China
Plan in China
Incorporate WFOE as a start to incubate Chinese patent CN109862905A published last 2019 06 07and proceed with Mainland fundraise to sponsor- Finished Pharmaceutical manufacturing operations in China- Engage discussions with Central NMPA to approve our Chinese Clinical Trial designBringing earlier access for Chinese patients to such first therapeutic treatment of OsteoArthritis of the knee,through out licensing to a major Chinese pharmaceutical company
Biotech/Pharma Category
Assets Information 1: Name|Description|Indications|Stage|IP countries
IP registered Mainland China in 2019
Biotech/Pharma Asset Stage
Medtech Category
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
First in Class new MoA peptide based DMOAD
Medtech Information 2
NeuroEndocrine Tumors
Target Client Type
Chinese pharma with established market position in OsteoArthritis
Slides Deck
(png, 430.99KB)
Dr Matthieu CHAREYRE
Dr Matthieu CHAREYRE
LinkedIn logo Chief Business Development Officer - Global Pharmaceutical Operations 
Functionality

Reistone Biopharma China

Reistone BioPharma is a clinical-stage biotech company focused on developing innovative medicines in autoimmune and autoinflammatory diseases. We are headquartered in Shanghai, China and have offices in Beijing, China as well in Boston and Chicago, US. Our current pipeline includes 4 small molecules in autoimmune and inflammatory diseases where significant gaps exist. The leading asset, a potent selective JAK1 inhibitor, recently completed global phase 2 trials in China, US and Europe in atopic dermatitis, ulcerative colitis and Crohn’s disease.

Currently we are looking for either partnership to develop the AD and/or UC or CD indications for phase 3 or out-license the global right excluding China market.
Company Size (Fulltime employees)
Please specify your partnering goal
Looking to in-license / out-license
Headquartner in China
Biotech/Pharma Asset Stage
Paul Chen
Chief of Staff 
Functionality

REM Analytics SA Switzerland

REM Analytics is a research and development service organisation, helping our customers develop and commercialise new products fast.
Having developed a series of core proprietary technologies, we deploy them to guarantee our customers the shortest time from concept to market. Our areas of focus are the development of personalised nutrition solutions, active food ingredients, functional cosmetics and agriculture.
Year of foundation
2020
Please specify your partnering goal
Identifying partners to jointly develop new products and services
Headquartner in China
Plan in China
Our goal is to identify innovation driven companies with whom to partner for joint development projects.
Assets Information 1: Name|Description|Indications|Stage|IP countries
ATGC|Microbniome analysis platform||Deployed and functioning|
Assets Information 2
ACIMA|Advanced Clinical data acquisition platform|Personalised medicine|Prototype test in progress|
Paulo Refinetti
Dr. 
Functionality

Research Institute of Tsinghua University in Shenzhen China

The Research Institute of Tsinghua University in Shenzhen (RITS) was founded in 1996. RITS strives to establish an innovation incubation system and an industrial investment platform open to both China and abroad, cultivating strategic emerging industries.
Company Size (Fulltime employees)
Year of foundation
1996
Looking for
Please specify your partnering goal
hi-tech projects and enterprises with landing needs
Headquartner in China
Medtech Development Stage
Qi Gong
Project manager 
Functionality

ResoTher Pharma ApS Denmark

ResoTher Pharma is a privately held biotechnology company located in Copenhagen, Denmark. The company is focused on developing peptide-based drugs derived from the endogenous immunomodulator Annexin A1 as resolution therapy for diseases where neutrophil-driven inflammation plays a key pathological role. Our current focus is on cardiovascular disorders and inflammatory disorders with a large unmet medical need. Our lead asset is ready for clinical development in 2021 and expect to reach PoC in myocardial infarction within 3 years.
Year of foundation
2016
Please specify your partnering goal
Interested in Pharma collaborators focused on cardiology, vascular inflammation, stroke and who wish to acquire Asia rights
Funding Status
Funded to complete preclinical development, raising funds to cover phase I - phase II POC
Now raising (In USD)
5-15M
Headquartner in China
Plan in China
We seek: - equity investment of € 5-15M to fund our clinical development - a co-development agreement for our lead compound in STEMI or adjacent cardiovascular indications with the goal to divest China/Asia rights in the given indication.
Assets Information 1: Name|Description|Indications|Stage|IP countries
RTP-026|Peptide|STEMI|Phase I ready|NA
Lone Veng
CEO 
Functionality

Respinova Ltd. Israel

Respinova has developed a novel non-invasive technology that aims to treat the core of the COPD pathophysiology – small airway collapse.

Respinova's solution uses unique pulses of air pressure generated by a proprietary device called PulseHaler™. ​The small airways have no cartilage structural support and are totally dependent on the tethering forces of the surrounding lung. When these forces are diminished, the small airways collapse and do not permit airflow to the gas-exchanging alveolar zone of the lung. When COPD starts, airways initially reopen on inspiration. Once the disease progresses, the airways open only on deep inspiration, and finally not at all. When the small airways collapse, not only is gas exchange is impaired, but also the cilia clearing mechanism fails, and secretions accumulate to further worsen the situation.

The small airways have little or no smooth muscle in their walls so that neither beta-adrenergic nor muscarinic drugs can open them up, even if the particles manage to be delivered to the small airways.

The PulseHaler™ generates proprietary pressure pulses that travel into the lung which propagate faster inside the airways than in the surrounding parenchyma, thereby creating multiple momentary dilating forces that help gently pry open the collapsed airways. PulseHaler™ also generates positive pressure on exhalation, which helps with airway opening. The pulses also help in smoothing and spreading the mucus lining layer on the airways walls, which assists in airway clearance and reduces the tendency of airways to re-close.

Company Size (Fulltime employees)
Funding Status
Serial B
Now raising (In USD)
$ 10MM
Headquartner in China
Biotech/Pharma Category
Medtech Category
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
Pulsehaler | Pulsehaler™ is a novel treatment that uses Dynamic Air Pressure Pulses to re-open closed airways,improve exercise capacity and Quality of Life in COPD patients. | NDA |
Medtech Development Stage
Cliff Ansel
CEO 
Functionality

Rius Medical UG (Haftungsbeschränkt) Germany

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!
Company Size (Fulltime employees)
Year of foundation
2016
Looking for
Please specify your partnering goal
Bring together technology & funds for improving “China Focus” healthcare situation on an equal basis.
Funding Status
Seeking investors for Series A
Now raising (In USD)
1,665,454 USD
Headquartner in China
Plan in China
Rius Medical unique position as CDMO (contract development and manufacturing organization) is not limited to drug delivery. Yes, drug delivery programs bring EUR 130 million revenue sooner than “Rius Medical’s blood transfusion” program. However, Rius Medical’s path to becoming a market leader in healthcare in promoting excellence, innovation and good business practices, is driven by its “blood transfusion” program. The Plan in China is local Jobs in China for manufacturing of stem cells derived “blood transfusion” products. Also drug delivery via "Third-Generation red blood cells for drug delivery" that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes, is region-specific; as in Europe, USA and China regions due to ABO blood group and other antigens being region-specific!
Assets Information 1: Name|Description|Indications|Stage|IP countries
eRBC|Red Blood Cells for Drug Delivery|Oncology|Prototype Assembly|N/A
Biotech/Pharma Asset Stage
Mr Denis Demarais
Mr Denis Demarais
LinkedIn logo Founder and CEO 
Functionality